Experience

ACELYRIN Announces Pricing of Upsized Initial Public Offering

May 15, 2023

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Read more

Related contacts

Chadwick Mills
Partner, San Francisco
Charlie Kim
Partner, San Diego
Anitha Anne
Associate, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Alexander Lee
Partner, Los Angeles Santa Monica
Joshua Mates
Partner, San Francisco
Phil Mitchell
Partner, New York
Brad Goldberg
Partner, New York
Peter Adams
Partner, San Diego
Lauren Creel
Partner, Palo Alto
Koji Fukumura
Partner, San Diego
Patrick Gibbs
Partner, Palo Alto
David Peinsipp
Partner, San Francisco
Barbara Borden
Partner, San Diego
David Navetta
Partner, Colorado
Patrick Van Eecke
Partner, Brussels
Shannon Eagan
Partner in Charge – Palo Alto, Palo Alto
Darren DeStefano
Partner, Reston
Francis Wheeler
Partner, Colorado
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Brett White
Of Counsel, Palo Alto
Dani Nazemian
Special Counsel, San Diego
Jennifer Shanley
Special Counsel, New York
Jacquelyn Burke
Special Counsel, Boston
Karen Tsai
Special Counsel, Washington DC
Miriam Petrillo
Special Counsel, Chicago
Andrew Nelms
Associate, San Francisco
Amy Mao
Associate, San Francisco
David D. Kim
Associate, San Francisco
Lawrence Traylor
Associate, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego
Nathaniel Hearn Jr.
Associate, New York
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Eileen Leman
Associate, Los Angeles Downtown
Kelly McCormick
Associate, San Francisco
Mor Agam
Associate, New York
Allison Kutner
Associate, New York
Madison (JJ) Meng
Associate, San Francisco
Rebecca Siegel
Associate, San Francisco
Rachel F. Katz
Associate, New York
Mari Dugas
Associate, Washington DC
Loriane Sangaré-Vayssac
Associate, Brussels
Megan Drill
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Kristin R. Marshall
Associate, Washington DC
John T. Stellini
Associate, Palo Alto
Luke X. Blackett
Associate, San Francisco

Erasca – $100 Million Follow-on Offering

January 9, 2023

Cooley advised the underwriters in Erasca’s $100 million follow-on offering of 15,384,616 shares of common stock at a public offering price of $6.50 per share. Erasca is a clinical-stage biopharmaceutical company discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Kristin VanderPas and Denny Won led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Amy Mao
Associate, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
Julia Gage
Associate, San Francisco

Ascendis Pharma – $460 Million Follow-On Offering

September 30, 2021

Cooley advised the underwriters on Ascendis Pharma’s $460 million follow-on offering. J.P. Morgan Securities, Morgan Stanley, Evercore Group, and SVB Leerink acted as joint book-running managers for the offering. Ascendis is a biopharmaceutical company applying its TransCon technologies to create new and potentially best-in-class therapies. Partners Jonie Kondracki, Charlie Kim, and Div Gupta led the Cooley team representing the underwriters.

Related contacts

Jonie Ing Kondracki
Partner, San Francisco
Charlie Kim
Partner, San Diego
Div Gupta
Partner, New York
Denny Won
Partner, San Francisco
Amy Mao
Associate, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica

Erasca – $345 Million IPO

July 16, 2021

Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Amy Mao
Associate, San Francisco
David D. Kim
Associate, San Francisco
Julia Gage
Associate, San Francisco
Kim Merritt
Paralegal Specialist, San Francisco
Madhuri Roy
Partner, Palo Alto

Singular Genomics Systems – $258 Million IPO

May 27, 2021

Cooley advised the underwriters on Singular Genomics Systems’ $258.1 million initial public offering of 11,730,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. UBS Securities acted as a book-running manager for the offering, and J.P. Morgan Securities, Goldman Sachs, BofA Securities, and Cowen and Company acted as joint book-running managers. Singular Genomics Systems, whose securities now trade on the Nasdaq Global Select Market  under the symbol OMIC, is a life sciences technology company. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Amy Mao
Associate, San Francisco
View more